Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1

(2011) Z. Hu et al.   JOURNAL OF VIROLOGY

A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus

(2011) HimaBindu Chunduri et al.   Virology Journal

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

(2010) Johan Vingerhoets et al.   AIDS

The M230L Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation in HIV-1 Reverse Transcriptase Impairs Enzymatic Function and Viral Replicative Capacity

(2010) H. T. Xu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes

(2010) Eugene L. Asahchop et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pre-calculated protein structure alignments at the RCSB PDB website: Fig. 1.

(2010) Andreas Prlić et al.   BIOINFORMATICS

Visualizing the Molecular Interactions of a Nucleotide Analog, GS-9148, with HIV-1 Reverse Transcriptase–DNA Complex

(2010) Eric B. Lansdon et al.   JOURNAL OF MOLECULAR BIOLOGY

I-TASSER: a unified platform for automated protein structure and function prediction

(2010) Ambrish Roy et al.   Nature Protocols

Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C

(2010) Hong-Tao Xu et al.   Retrovirology

Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1–Infected Patients

(2010) Rodger D. MacArthur   Current Infectious Disease Reports

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine

(2009) H. Xu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Etravirine, a Next‐Generation Nonnucleoside Reverse‐Transcriptase Inhbitor

(2009) Leonard B. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral Therapy

(2009) Jorge L Martinez-Cajas et al.   DRUGS

Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance

(2009) Kalyan Das et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs

(2009) Z. Ambrose et al.   JOURNAL OF VIROLOGY

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues

(2008) Eva Poveda et al.   AIDS

Reduced dNTP Binding Affinity of 3TC-resistant M184I HIV-1 Reverse Transcriptase Variants Responsible for Viral Infection Failure in Macrophage

(2008) Varuni K Jamburuthugoda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Apparent Defects in Processive DNA Synthesis, Strand Transfer, and Primer Elongation of Met-184 Mutants of HIV-1 Reverse Transcriptase Derive Solely from a dNTP Utilization Defect

(2008) Lu Gao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo

(2008) Javier Martinez-Picado et al.   VIRUS RESEARCH